Lunai Bioworks Inc.
LNAI evidence brief
What we can confirm
- Market Cap:
- $8.0M
What it means
What to watch
Prepared research question
What matters most for LNAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LNAI
Lunai Bioworks Inc. (LNAI) is a biology-first AI drug discovery company focused on AI-powered therapeutics and biodefense, with a recent strategic pivot and a Parkinson's disease platform, but faces significant financial challenges including negative shareholders' equity and a recent employee furlough.
Key risk: Negative equity
Market Cap
$8.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Lunai Bioworks Inc. (LNAI) is a biology-first AI drug discovery company focused on AI-powered therapeutics and biodefense, with a recent strategic pivot and a Parkinson's disease platform, but faces significant financial challenges including negative shareholders' equity and a recent employee furlough.
- Lunai Bioworks is a biology-first AI drug discovery company (Nasdaq: LNAI) [news · 2026-09-22].
- As of 2026-03-31, the company reported cash & equivalents of $3.2M, $0.0M revenue, net income of -$2.6M, and shareholders' equity of -$9.6M [sec].
- In September 2025, the company adopted a new corporate identity and strategic focus on AI-powered therapeutics and biodefense [news · 2025-09-30].
- In February 2026, Lunai implemented a temporary furlough of employees in the US and Canada to preserve liquidity [news · 2026-03-05].
- In September 2026, Lunai entered an exclusive worldwide license and collaboration agreement with Tanaist to add human cellular phenotyping to its Parkinson's disease platform [news · 2026-09-22].
What works
- Lunai has established a wholly owned subsidiary, BioSymetrics, with an AI platform (Augusta) used to identify patient subtypes for Parkinson's disease, and has secured an exclusive worldwide license with Tanaist to add human cellular phenotyping to its platform [news · 2026-09-22].
- The company has demonstrated AI-based chemical-risk screening capabilities, including a technical case study on predicting acetylcholinesterase inhibition from molecular structure, which could support biodefense applications [news · 2026-09-16].
- Lunai reported a significant reduction in net loss from approximately $178.0M in FY2025 to an anticipated ~$3.2M for FY2026, indicating a sharp reduction in operating losses [news · 2026-09-29].
What to weigh
- Lunai has negative shareholders' equity of -$9.6M as of 2026-03-31, indicating that liabilities exceed assets [sec].
- The company generated $0.0M in total revenue as of 2026-03-31, with a net loss of -$2.6M for that period [sec].
- In February 2026, Lunai implemented a temporary furlough of employees in the US and Canada to preserve liquidity while pursuing additional financing, signaling cash constraints [news · 2026-03-05].
- The company filed a non-timely 10-K for FY2026, indicating potential reporting or operational delays [news · 2026-09-29].
From the filings
Quoted directly from source documents.
Lunai Bioworks is a biology-first AI drug discovery company.
“Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company”
News · September 22, 2026
Lunai implemented a temporary employee furlough to preserve liquidity.
“implemented a temporary furlough of its employees in the United States and Canada as part of actions intended to preserve the Company's liquidity while it continues to pursue additional financing.”
News · March 5, 2026
Lunai entered an exclusive worldwide license and collaboration agreement with Tanaist for Parkinson's disease platform.
“announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform.”
News · September 22, 2026
Lunai reported a net loss of approximately $3.2 million for FY2026.
“The Company anticipates reporting a net loss for the fiscal year ended June 30, 2026 of approximately $3.2 million”
News · September 29, 2026
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$9.6M as of 2026-03-31 indicates liabilities exceed assets [sec].
- Zero revenue — Total revenue of $0.0M as of 2026-03-31 shows no product sales [sec].
- Liquidity crisis — Employee furlough in Feb 2026 to preserve liquidity while seeking financing [news · 2026-03-05].
- Late SEC filing — Filed a non-timely 10-K for FY2026, indicating reporting delays [news · 2026-09-29].
What to watch
- Whether Lunai secures additional financing to address liquidity constraints after the February 2026 furlough [news · 2026-03-05].
- Progress of the Tanaist collaboration and any resulting preclinical or clinical milestones for the Parkinson's disease platform [news · 2026-09-22].
- The company's ability to generate revenue from its AI platform or partnerships, given $0.0M revenue as of 2026-03-31 [sec].
- Any updates on the merger agreement with Neurobridge IP Holdings Incorporated entered in April 2026 [news · 2026-05-01].
Sources: News · Generated October 13, 2026 · How we verify sources →
Run Lunai Bioworks Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lunai Bioworks Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 28, 2026- % of float
- 2.5%
- Days to cover
- 0.0
- Shares short
- 779,601
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LNAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lunai Bioworks Inc.?
Lunai Bioworks Inc. (LNAI) is a biology-first AI drug discovery company focused on AI-powered therapeutics and biodefense, with a recent strategic pivot and a Parkinson's disease platform, but faces significant financial challenges including negative shareholders' equity and a recent employee furlough.
Who is the CEO of Lunai Bioworks Inc.?
Mr. David H. Weinstein is the chief executive officer of Lunai Bioworks Inc. (LNAI).
Where is Lunai Bioworks Inc. headquartered?
Lunai Bioworks Inc. (LNAI) is headquartered in Los Angeles, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.